Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03768492 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
A Phase 2 study of Carcinoma, Breast, sponsored by NYU Langone Health.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03768492 is a Phase 2 study of Carcinoma, Breast that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03768492, a Phase 2 study of Carcinoma, Breast, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of reconstructive complications in patients with tissue expander based reconstruction requiring post-mastectomy radiation therapy when compared to a placebo cream.
Conditions Studied
Interventions
- DRUG Caffeine anhydrous 5% added to Lipoderm Cream Base.
- OTHER Lipoderm Cream Base
Study Locations (1)
New York
- New York University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03768492
The ClinicalTrials.gov registry entry for NCT03768492 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Breast appearing as the primary indexed condition, and to 2 interventions - of which Caffeine anhydrous 5% added to Lipoderm Cream Base. is the first listed.
NCT03768492 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03768492 about?
NCT03768492 is a clinical study titled "Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy". The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of reconstructive complications in patients with tissue expander based reconstruction requiring post-mastectomy radiation therapy when compared to a placebo cream.
What is the current status of trial NCT03768492?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-06-29. Estimated completion is 2027-12.
What conditions does trial NCT03768492 study?
This clinical trial studies the following conditions: Carcinoma, Breast.
What interventions are being tested in trial NCT03768492?
The interventions under investigation include: Caffeine anhydrous 5% added to Lipoderm Cream Base. (DRUG), Lipoderm Cream Base (OTHER).
Who is sponsoring clinical trial NCT03768492?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03768492 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.